
Fragile X at a turning point: Breaking through the clinical bottleneck
In this episode of Denatured, you’ll hear from Hilary Rosselot, executive director at the National Fragile X Foundation and Jordi Fàbrega, co-founder & CEO at CONNECTA Therapeutics. From trial endpoints and placebo effects to neuroplasticity modulation, we explore what it will take to build a sustainable path to the first approved therapy. Host Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Hilary Rosselot, Executive Director, National Fragile X Foundation Jordi Fàbrega, Co-Founder & CEO, CONNECTA Therapeutics Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Publisher
BioSpace
Published
August 27, 2026
Duration
19 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
BioSpace
@biospace
#turningpoint #breaking #clinicalbottleneck #lifesciences
